Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Front Endocrinol (Lausanne) ; 15: 1411262, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39247915

RESUMEN

Background: Under the current pandemic of Corona Virus Disease 2019 (COVID-19), The relationship between fatigue and COVID-19 has been found. Infection with COVID-19 is associated with fatigue long after the acute phase of COVID-19. Understanding the association of thyroid hormones levels with post-COVID condition, such as fatigue, is necessary to improve quality of life. Methods: This population-based cohort study was conducted in Dalian, China, from December 2022, to March 2023, using a Yidu Core platform in the First Affiliated Hospital of Dalian Medical University, that integrates medical records, laboratory tests, and all diagnosis and treatment information based on patients in hospital. Eligible individuals were 40 patients with COVID-19, Divided them into fatigue group and non-fatigue group following up by telephone using the FS-14 scale after 6 months. The primary outcomes were the diagnoses of fatigue. The association between thyroid hormones levels and post-COVID condition, such as fatigue, was assessed using logistic regression analysis. Results: Compared with the non-fatigue group, the FT3 level in fatigue group was lower (p<0.05). FT3 was negatively correlated with fatigue after 6 months (OR 0.257, p<0.05). After adjusting for confounding factors such as age and gender, low FT3 was a risk factor for fatigue in patients with COVID-19, (OR 0.225, p<0.05). And the FT3 is less than 2.47 mol/L, it is the best critical value for predicting long-term fatigue, with a sensitivity of 92.3% and a specificity of 48.1%. Conclusions: Most people still have fatigue 6 months after COVID-19 infection. FT3 serves as the important index to predict fatigue in patients with COVID-19. it should be closely monitored during infection.


Asunto(s)
COVID-19 , Fatiga , Triyodotironina , Humanos , COVID-19/complicaciones , COVID-19/epidemiología , Fatiga/etiología , Fatiga/epidemiología , Femenino , Masculino , Persona de Mediana Edad , Triyodotironina/sangre , Adulto , China/epidemiología , SARS-CoV-2 , Anciano , Estudios de Cohortes
2.
RSC Adv ; 11(40): 24883-24891, 2021 Jul 13.
Artículo en Inglés | MEDLINE | ID: mdl-35481030

RESUMEN

A series of micro-mesoporous SSZ-13/CexWyTiz composites with different zeolite/oxide ratios were synthesized using a one-step crystallization method. The effects of the mass ratio on the crystal form, specific surface area, pore structure, surface element properties, redox properties, surface acidity and deNO x performance of the Cu-SSZ-13/CeWTi composite catalysts were investigated using X-ray diffractometry (XRD), Brunauer-Emmett-Teller analysis (BET), X-ray photoelectron spectroscopy (XPS), H2 temperature programmed reduction (H2-TPR) and NH3 temperature programmed desorption (NH3-TPD). The results reveal that the Cu-SSZ-13/CeWTi composite catalysts formed a micro-mesoporous structure. The increase in the mass ratio leads to the increased microporous ratio of the composite catalysts, the improved crystal structure of SSZ-13 and a higher specific surface area and pore volume, which is conducive to enhancing the low-temperature deNO x activity, but its high-temperature performance (450 °C and above) decreases. The introduction of micropores into mesoporous materials can result in the production of more Ce4+, surface chemisorption oxygen species Oα and acid sites. The Cu-SSZ-13/CeWTi composite catalyst with a mass ratio of 1 : 4 demonstrated the best micro-mesoporous ratio, low-temperature selective catalytic reduction (SCR) performance and hydrothermal stability.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA